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In this study we investigated telomere
restriction fragment (TRF) length in a
panel of mature B-cell lymphoprolifera-
tive disorders (MBCLDs) and correlated
this parameter with histology and his-
topathogenesis in relation to the germinal
center (GC). We assessed 123 MBCLD
samples containing 80% or more tumor
cells. TRF length was evaluated by South-
ern blot analysis using a chemilumines-
cence-based assay. GC status was as-
sessed through screening for stable and
ongoing somatic mutations within the
immunoglobulin heavy-chain genes. Me-
dian TRF length was 6170 bp (range,
1896-11 200 bp) and did not correlate with
patient age or sex. TRF length was greater
in diffuse large cell lymphoma, Burkitt
lymphoma, and follicular lymphoma (me-
dians: 7789 bp, 9471 bp, and 7383 bp,
respectively) than in mantle cell lym-
phoma and chronic lymphocytic leuke-
mia (medians: 3582 bp and 4346 bp, re-
spectively). GC-derived MBCLDs had the
longest telomeres, whereas those arising
from GC-inexperienced cells had the
shortest (P < 109). We conclude that (1)
TRF length in MBCLD is highly heteroge-
neous; (2) GC-derived tumors have long
telomeres, suggesting that minimal telo-
mere erosion occurs during GC-derived
lymphomagenesis; and (3) the short TRF
lengths of GC-inexperienced MBCLDs in-
dicates that these neoplasms are good
candidates for treatment with telomerase
inhibitors, a class of molecules currently
the subject of extensive preclinical evalu-
ation. (Blood. 2004;103:4644-4649)
© 2004 by The American Society of Hematology
Introduction
Telomeres are repeated DNA sequences at the ends of chromo-
somes in eukaryotic cells, and they play a critical role in maintain-
ing chromosomal stability.1-6 In most somatic cells, they shorten at
each mitotic division as a result of the inability of DNA polymerase
to synthesize open extremities of DNA.2-7 As the number of
divisions increases, telomere restriction fragment (TRF) length
falls beyond a critical value, leading to senescence, a peculiar phase
of cell life mostly characterized by growth inhibition.8-10 Senes-
cence is distinguished by low proliferative activity and is regarded
as an important checkpoint in somatic cell life. If the senescence
checkpoint is bypassed (eg, through p53 Rb1 inactivation), cells
continue to divide until they reach a second proliferative barrier
named crisis. Crisis is associated with genetic instability, chromo-
somal fusions, and a high tendency toward apoptosis and malignant
transformation.11-13
The telomeres of germinal cells are preserved from shortening
by an enzymatic RNA-containing complex called telomerase,
whose catalytic subunit (h-TERT) has intrinsic reverse transcrip-
tase capability and adds repeated DNA sequences to chromosomal
ends.1,14-18 Telomerase is usually not expressed in somatic cells,
with few exceptions characterized by high replicative potential.15-18
In addition, telomerase activity (TA) is often turned off during
differentiation, even in cell subtypes in which there is significant
h-TERT activity during early development.16,17 This is probably
related to the limited proliferative potential of terminally differenti-
ated cells. B cells are a notable exception to this rule. Naive B cells
have no detectable TA, whereas strong telomerase activation is
observed in germinal center (GC)–derived B cells. This is probably
related to the high mitotic activity of GC cells.19 In post-GC
maturation, increased TA is still observed in some subtypes, but its
level is lower than during GC maturation.19 This peculiar aspect of
B-cell development is reflected by TRF length in normal B cells.
No GC erosion occurs in GC B cells despite proliferative activity
that is among the highest ever observed in human cells.19
During tumorigenesis, telomeres usually undergo progressive
shortening until TA is restored to allow indefinite cell replica-
tion.20,21 This late activation is now regarded as a critical step in
tumor development, and telomerase is considered to play a crucial
role in sustaining neoplastic cell survival.1,21-23 This explains why
most tumors are characterized by short telomeres despite the
presence of high TA levels. This peculiar feature of cancer cells has
suggested that telomerase inhibition could be a good approach to
slow down cancer replication and ultimately to induce selective
cancer cell death.1,24-26
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In contrast to findings in solid tumors, few data have been
accumulated on TRF lengths in mature B-cell lymphoproliferative
disorders (MBCLDs). Studies have been primarily restricted to
multiple myeloma27 and chronic lymphocytic leukemia,28,29 but
TRF lengths in MBCLDs as a whole have not been quantified. The
aim of this study was to determine TRF lengths in a large panel of
mature B-cell tumors and to assess the link between TRF length
and tumor histopathogenesis in relation to the GC. Patients were
evaluated for TRF length and GC status (ie, pre-GC, GC-derived,
and post-GC) according to the presence of stable or ongoing
somatic mutations within the variable regions of immunoglobulin
heavy-chain genes (VH).
Patients, materials, and methods
Patient and sample characteristics
One hundred twenty-three tumor samples from 117 patients with MBCLD
of 7 subtypes, displaying 80% or more neoplastic infiltration by flow
cytometry, were used. Twenty-two were from peripheral blood (PB), 44
from bone marrow (BM), and 57 from lymph nodes (LNs). Samples
obtained from different tissues during the same disease phase were
available for 6 patients (BM vs PB in 2 patients, BM vs LN in 3 patients,
and PB vs LN in 1 patient). Diagnoses was made in accordance with World
Health Organization (WHO) classification.30 Our panel consisted of 9
patients with mantle cell lymphoma (MCL), 31 with chronic lymphocytic
leukemia (CLL), 31 with follicular lymphoma (FL), 5 with Burkitt
lymphoma (BL), 14 with diffuse large-cell lymphoma (DLCL), 9 with
marginal zone lymphoma (MZL), and 18 with multiple myeloma (MM)
(with PB features of plasma cell leukemia [PCL] in 6). All diagnoses were
established by the same hemopathologist, who was unaware of the TRF
length results when defining the subtypes. Diagnosis was always supported
by histology and flow cytometry. Immunohistochemistry, cytogenetics, and
molecular biology analyses were also performed, if required, according to
the WHO criteria.30 Samples were taken at diagnosis in 80 patients and after
treatment in 37 patients. Samples taken after treatment were obtained at true
relapse (occurring after a previous complete or very good partial remission)
in 20 patients and during disease progression or stable disease in 7. Ten
CLL patients were partial responders still displaying more than 80% tumor
contamination in BM or PB (partial response was defined according to
Cheson et al31 as a 50% reduction in PB lymphocytes, with total resolution
of BM failure if present). Patient demographic and clinical characteristics
are shown in Table 1.
Cell line and DNA extraction
The MM cell line KMS-11 (kindly provided by Massimo Massaia,
University of Turin, Italy), which has a TRF length of 3420 bp, was used for
dilution tests against PB mononuclear cells from a healthy donor. BM and
PB mononuclear cells were separated by Ficoll-Hypaque density gradient
centrifugation. Lymph node tissue was always obtained from fresh or
frozen samples. Genomic DNA was extracted using the DNAzol reagent
(Gibco BRL Life Technologies, Grand Island, NY) according to the
manufacturer’s recommendations.
Determination of TRF length
TRF length was determined using Southern blot analysis according to the
following procedure. Aliquots of 2 g DNA were digested by mixing HinfI
(20 MU) and RsaI (20 MU) (Roche Diagnostics, Mannheim, Germany) for
2 hours at 37°C, according to the manufacturer’s recommendations. TRF
were then separated by 0.8% agarose gel electrophoresis in 1 TAE buffer
(pH 8.0). Gels were transferred to a positively charged nylon membrane
(catalog no. 1 417 240; Roche Diagnostics) and were ultraviolet (UV) light
cross-linked for 10 minutes. Hybridization was performed with the
TeloTAGG Telomere Length Assay Kit (Roche Diagnostics), which con-
tains all the reagents required. Membranes were prehybridized for 2 hours
in the prehybridization solution at 62°C and then hybridized for 3 hours in
the same conditions by adding 2 L of the digoxigenin (DIG)–labeled
telomere-specific probe. After hybridization, filters were washed twice at
room temperature for 15 minutes in 2 washing solution and then twice at
39C° in 0.5  washing solution for 20 minutes. Filters were then incubated
with a DIG-specific antibody covalently coupled to alkaline phosphatase
(AP). Finally, results were visualized using AP metabolizing CDP-Star, a
highly sensitive chemiluminescent substrate. The light signal produced on
the site of the hybridized probe was recorded on x-ray film (Lumi-Film
Chemiluminescent Detection Film; Roche Diagnostics). Each assay was
performed twice. Membranes were then scanned and analyzed with Kodak
Digital Science 1D Image Analysis Software (Scientific Imaging Systems,
New Haven, CT). Two different parameters were calculated for each
telomere smear. The first was mean TRF length, calculated as already
described.7,32,33 The second was peak TRF length, the point of maximum
signal intensity defining the highest concentration of telomere repeats.
These 2 parameters were assessed to minimize any bias associated with
contaminating nonneoplastic cells. Percentages were always 20% or less
and were thus not expected to influence the peak values, whereas they could
have influenced the extremities of the smear, thus potentially biasing
calculation of mean TRF length.
VH sequencing analysis
Tumor-specific VH rearrangements were amplified starting from genomic
DNA or, for MM and PCL only, from immunoglobulin-specific cDNA as
previously described.34-36 Primers and PCR conditions for VH amplification
have been previously described.34,37 Briefly, 1 g genomic DNA or 2 L
cDNA were amplified using 3 sets of consensus forward primers, 2 derived
from the framework region 1 (FR1) and 1 from the leader region, together
with a J consensus region antisense primer.34,37 The reaction was carried out
for 30 to 33 cycles with denaturation at 94°C for 1 minute, annealing at
62°C for 30 seconds, and extension at 72°C for 30 seconds, with a final
extension of 10 minutes at 72°C. PCR products were then analyzed by
electrophoresis on 2% agarose gels. When an apparently clonal PCR
product was observed, the sample of interest was reamplified on a large
scale for direct sequencing of the tumor immunoglobulin H (IgH) rearrange-
ment. Purification of polymerase chain reaction (PCR) products, direct
Table 1. Characteristics of samples and patients
Histology
No.
samples*
Sample type, no.
No.
patients*
Sex, no.
Age
Clinical status
LN BM PB M F
Younger
than 30 y 30-49 y 50-69 y
Older
than 70 y Diagnosis After treatment
CLL 34 7 10 17 31 20 11 0 5 21 5 13 18
MCL 10 9 1 0 9 7 2 0 0 5 4 9 0
FL 33 19 13 1 31 20 11 1 8 18 4 12 19
BL 5 2 3 0 5 4 1 1 2 2 0 5 0
DLCL 14 13 1 0 14 7 7 1 2 7 4 14 0
MZL 9 7 0 2 9 5 4 0 2 3 4 9 0
MM 18 0 16 2 18 11 7 0 3 10 5 18 0
Total 123 57 44 22 117 74 43 3 22 66 26 80 37
*For 2 patients with FL, 3 with CLL, and 1 with MCL, 2 different tissues obtained during the same treatment phase were available.
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sequencing reactions, and sequence analysis were performed as previously
described.36,37
VH analysis for somatic mutations
Mutation analysis of the VH region was then performed as follows:
nucleotide sequences were aligned to the V-Base sequence directory (MRC
Centre for Protein Engineering, Cambridge, United Kingdom) (http://
www.mrc-cpe.cam.ac.uk/vbase-ok.php?menu 901). Percentage of homol-
ogy was calculated by counting the number of mutations between the 5 end
of FR1 and the 3 end of FR3, as previously described.38 Sequences with
2% or less deviation from any germline VH sequence were considered
unmutated and, thus, as belonging to GC-inexperienced cells. Sequences
containing more than 2% deviation from any known germline VH were
considered mutated and were defined as GC experienced. Patients failing
VH sequencing were excluded from further analysis.38
Evaluation of the presence of ongoing SHM
The presence of the ongoing somatic hypermutation (SHM) mechanism
was evaluated in all samples, defined as GC-experienced MBCLD to
distinguish GC-derived from post-GC–derived MBCLD. Clonal VH rear-
rangements were amplified with appropriate primers and cloned into the
pCR4-TOPO plasmid vector (Invitrogen, Paisley, United Kingdom). Twenty
or more randomly chosen bacterial clones were expanded into LB medium
overnight. Three milliliters culture medium was purified with Wizard Plus
Minipreps DNA Purification System (Promega). Plasmids were then
sequenced by IRBM (Servizio Sequenziamento Automatico, Pomezia,
Roma, Italy). Only clones with identical or nearly identical CDR3 were
considered. Substitution mutations observed in only 1 clone and in more
than 1 clone were classed as unconfirmed and confirmed mutations,
respectively.39 Only confirmed mutations were considered evidence of
ongoing SHM; unconfirmed mutations were disregarded.40-42
Results
Validation of the modified strategy for the calculation
of peak TRF length
Because the patient samples were not purified, we had concerns
about the potential confounding role of contaminating nonneoplas-
tic cells on calculations of peak TRF length. To validate our
strategy, dilution tests with the KMS-11 cell line were performed.
Cancer cells were diluted on a background of PB mononuclear cells
from a healthy donor (50-year-old man). The dilution test was
performed by calculating peak TRF length on samples containing
tumor cells in 5% increments from 50% to 100%. The same
experiment was performed 3 times. For the purposes of this study,
TRF measurements were considered acceptable if those of the
contaminated cell samples were 5% or less different from those in
the sample containing 100% tumor cells. Peak TRF of samples
containing 5%, 10%, 15%, 20%, 25%, 30%, 35%, and 40%
contaminating cells showed median increases in peak TRF length,
respectively, of 1.5%, 2.0%, 2.3%, 3.0%, 3.8%, 4.6%, 8%, and
16%. Samples containing 45% and 50% contaminating cells
showed a bimodal aspect with 2 peaks of similar size, as would be
expected from cell populations containing similar amounts of
cancer cells and healthy cells. Based on these results, peak TRF
values were close enough to the expected rate up to contamination
of 30% nonneoplastic cells. In contrast, mean TRF length was
acceptable only up to a contamination of 20% (data not shown).
Thus, both approaches were appropriate for TRF length calculation
in our panel, though peak TRF values were more accurate.
TRF lengths in the whole MBCLD population
The mean value of peak TRF length in our population was 6170 bp.
The population was heterogeneous, with a standard deviation
of  1985 bp. Median TRF length was 6060 bp (range, 1896-
11 200 bp). The 10th, 25th, 75th, and 90th percentiles were 3334,
5100, 7755, and 8725 bp, respectively. A representative example of
TRF length analysis is shown in Figure 1. Demographic features
were not predictive of TRF length. In particular, TRF length of
MBCLD samples was not associated with patient age when the
entire population was considered (r2  0.0783) (data not shown).
In addition, when analysis was performed separately on each
disease subtype, we did not observe higher TRF lengths in young
patients than in older ones (data not shown). Similarly, sex had no
influence on TRF length (data not shown). No significant differ-
ences in TRF lengths were apparent between samples taken at
diagnosis and those taken after treatment of the 2 disorders (FL and
CLL) in which samples from treated patients were available (CLL
at diagnosis: median peak TRF length, 5102 bp; range, 2162-8211
bp; CLL after treatment median peak TRF length, 4120 bp; range,
2253-7900 bp; P  .94) (FL at diagnosis: median peak TRF length,
7367 bp; range, 5355-8725 bp; FL after treatment median peak
TRF length, 7475 bp; range, 4361-10 030 bp; P  .95). In 6
patients TRF length was assessed on different tissues, but always
with identical results (Figure 1; patient C1437).
TRF length according to histology
Remarkable differences in peak TRF length were observed be-
tween the histologic subtypes (Figure 2). Patients with FL, BL, and
DLCL had the highest values, and their median and range values
were 7383 bp (range, 4361-10 030 bp), 9471 bp (range, 7052-
11 200 bp), and 7789 bp (range, 5244-10 304 bp), respectively. In
Figure 1. Representative example of TRF length in 6 MBCLD patients. Peak TRF
lengths are expressed as base pairs (bp). MW indicates molecular-weight ladder;
BM, bone marrow; PB, peripheral blood. C1336 and C1254 are CLL patients with
mutated VH; C1437 and C1025 are CLL patients with unmutated VH (C1437 includes
C1437BM and C1437PB); MM1387 is a MM patient; D1286 is a DLCL patient.
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contrast, MCL and CLL patients had short telomeres, often close to
the critical threshold of senescence. Their median and range values
were 3582 bp (range, 1896-8961 bp) and 4346 bp (range, 2094-
8211 bp), respectively. MZL and MM displayed intermediate TRF
lengths: 5969 bp (range, 5058-6681 bp) and 6283 bp (range,
4917-8900 bp). The telomeres of aggressive lymphomas were not
shorter than those of indolent subtypes. When indolent lymphomas,
namely those with overall survival longer than 3 years when treated
conventionally (CLL, FL, MZL), were compared with aggressive
subtypes (median survival less than 3 years with conventional
treatment) (BL, DLCL, MCL), a modest trend toward greater TRF
length was noted for the aggressive subtypes (P  .03) (data
not shown).
TRF length according to GC experience
Given that several histologic subtypes (including MCL, CLL,
DLCL, and MZL) are highly heterogeneous in terms of GC
experience of cell of origin, we looked for associations between
GC status and significant differences in TRF length. The presence
of stable and ongoing somatic mutations in the VH genes of all
patients was determined, as shown in Figure 3. VH sequencing was
successful in 100 of the 117 (85%) patients. Patients for whom VH
sequencing failed were excluded from further evaluation. Patients
showing homology greater than 98% to any known VH sequence
were classified as GC inexperienced. Seventy-two (72%) patients
defined as GC experienced underwent further cloning to assess the
presence of ongoing SHM and were subsequently classified as GC
derived (ongoing SHM-positive) or post-GC derived (ongoing
SHM-negative). Figure 4 indicates how subtypes were classified
according to mutational status. TRF length according to mutational
status is represented in Figure 5. GC-inexperienced tumors were
compared with GC-experienced tumors (Figure 5A). GC-inexperi-
enced tumors had shorter telomeres than GC-experienced tumors
(P  1010). GC-experienced tumors were further divided into
GC-derived and post-GC–derived tumors (Figure 5B). GC-derived
tumors had greater peak TRF lengths than GC-inexperienced
(P  109) and post-GC–derived tumors (P  .004). In addition,
post-GC–derived tumors appeared to have longer TRFs than
pre-GC MBCLD (P  106). As expected, TRF length was also
associated with mutational status in CLL patients. Telomeres were
significantly longer in the VH-mutated subtype (P  104) (Figure
5C). Of note, the association between TRF length and GC status
existed when only patients at diagnosis were considered (GC
experienced vs GC inexperienced [P  107]; pre-GC vs GC-
derived [P  105]; pre-GC vs post-GC [P  103]; GC-derived
vs post-GC–derived [P  .05; data not shown]). The relationship
between disease aggressiveness and TRF length was assessed
within both subgroups, and no difference was noticed (indolent
pre-GC–derived vs aggressive pre-GC–derived; P  .71; indolent
GC-derived vs aggressive GC-derived; P  .11; indolent post-GC–
derived vs aggressive post-GC–derived; P  .13). Results were
similar when mean rather than peak TRF lengths were considered
(data not shown).
Discussion
This study is the first comprehensive evaluation of TRF length in
all the most frequent histologic MBCLD subtypes. TRF length was
found to be highly heterogeneous among different subtypes of
MBCLD. FL, DLCL, and BL have long telomeres (median peak
TRF length, 7580 bp), whereas MCL and CLL have short telomeres
(median peak TRF length, 4116 bp) that are often close to the
critical threshold of senescence. Our main finding is that a high
peak TRF length is typical of lymphomas arising from the GC as
Figure 3. Experimental strategy for defining histopathogenesis of samples
according to GC origin.
Figure 4. Classification according to GC experience of MBCLD subtypes. White,
black, and gray sections represent the percentages of GC-inexperienced tumors,
GC-derived tumors, and post-GC–derived tumors, respectively.
Figure 2. Peak TRF length according to MBCLD histotype. There are marked
differences between the subtypes. Box plots indicate 25th percentile, median value,
and 75th percentile (horizontal lines of rectangle from the bottom, respectively) and
10th and 90th percentiles (horizontal lines outside rectangle).
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opposed to other MBCLD, particularly those arising from GC-
inexperienced cells. This suggests that GC-derived lymphomagen-
esis occurs in the absence of the marked telomeric loss often
associated with neoplastic transformation.
Telomere status has been extensively investigated in solid
tumors, but few reports have addressed the same issue in MBCLD,
and none have comprehensively investigated it in a large panel of
MBCLD, including the most important entities in the WHO
lymphoma classification.20-22,30 Some studies have looked at CLL
and MM.27-29 Bechter et al28 investigated TRF length in 58 CLL
patients and found that long telomeres are associated with favor-
able clinical features and better survival.28 In MM, Wu et al27
observed that samples displaying reduced TRF lengths have worse
outcomes. It has been concluded that short telomeres are mainly a
consequence of increased proliferative activity, usually observed in
patients with more aggressive disease. However, the association
between short telomeres and worse outcomes in CLL is largely
explained by the fact that patients with poor-prognosis, VH-
unmutated, GC-inexperienced CLL cells have shorter telomeres
than patients with VH-mutated CLL, as clearly shown in the recent
papers by Damle et al29 and Hultdin et al.43 Our results conclusively
demonstrate that the most important feature influencing telomere
length in MBCLD is tumor histopathogenesis, with particular
respect to GC experience. They also point to a minor role for
high-proliferative activity as a basic determinant of TRF length in
MBCLD. The peak TRF length of indolent histotypes, in fact, was
no greater than that of aggressive histotypes, and the telomeres of
highly proliferating MBCLDs, namely BL and DLCL, were longer
than those of slowly proliferating disorders, such as CLL. Of note,
no difference in TRF length could be associated with disease
aggressiveness when MBCLDs characterized by similar histopatho-
genesis were compared. However, a different proliferative activity
may explain TRF differences within a well-defined histopathologic
entity, as suggested by Wu et al27 for MM.
The mean TRF length of GC-derived normal B cells is slightly
(fewer than 1000 bp in 4 of 5 patients), though consistently, greater
than that of naive B cells.19 However, this does not explain the large
difference (4000 bp) between their neoplastic counterparts.19,44
Comparing our results with those of Weng et al19 in normal B cells
shows that GC lymphomagenesis is associated with an approxi-
mate telomeric loss of fewer than 2000 bp. In contrast, lym-
phomagenesis in GC-inexperienced B cells is associated with a loss
of more than 4000 bp and, hence, a TRF length close to the critical
senescence threshold. The remarkable telomere preservation in
GC-derived tumors should probably be attributed to the presence of
high TA in the parent GC B cell, clearly demonstrated by Weng et
al.19 However, the role of additional factors might be also
important, in particular telomere-binding factors such as TRF1,
TRF2, and Pot1.1 Because an effective telomere-preserving machin-
ery is a basic step for neoplastic transformation, it can be
speculated that during GC lymphomagenesis, one of the critical
checkpoints that plays a protective role against neoplastic trans-
formation is turned off “by default” because of the peculiar
biologic features of GC-derived B cells.1,45 This feature, together
with the heavy proliferative activity and the genetic instability
associated with VH switching and ongoing SHM, may explain
why GC-associated MBCLDs form the vast majority of human
B-cell neoplasms.
TRF length in post-GC–derived tumors was intermediate be-
tween the 2 previously mentioned subgroups. Most samples show
similar results of approximately 6000 bp. Post-GC–derived normal
B cells have TRF lengths of approximately 8500 bp.19 Our findings
indicate that telomeric loss in post-GC lymphomagenesis is
approximately 2500 bp. This value is definitely lower than in
GC-inexperienced cells. This difference can be explained by the
presence of residual TA in parent post-GC cells and by more rapid
restoration of TA during lymphomagenesis. The observation that
memory B cells have low or no TA suggests that the second
hypothesis is more reasonable, at least for CLL. Nevertheless, the
remarkable TRF length homogeneity of post-GC MBCLD remains
an intriguing finding. This subgroup is the most heterogeneous of
the 3 because it includes patients with 6 different subtypes (all but
BL) who have little in common biologically and clinically.
However, despite such important differences, these tumors undergo
a remarkably similar degree of telomere erosion during
lymphomagenesis.
We studied 80 samples taken at diagnosis and 37 taken after
treatment. We noticed no significant difference in terms of TRF
length between the 2 subgroups, in seeming contradiction to a
previous report by Remes et al,46 who observed significant
telomeric differences when samples obtained at diagnosis were
compared with those obtained at relapse. This apparent contradic-
tion can probably be explained by 2 factors. First, in our panel, only
a fraction of patients had true relapses, whereas several samples
were obtained from partial responders and patients with progres-
sive or stable disease. Second, our panel of treated patients had
only indolent neoplasms, whereas the population described by
Remes et al46 consisted mostly of patients with aggressive tumors.
It is reasonable to speculate that significant variations in TRF
length may occur after chemotherapy only in the presence of
marked cytoreduction. This might allow the selection of specific
tumor populations with TRF lengths different from those observed
at diagnosis. Compared with those described by Remes et al,46 our
patients underwent minor degrees of cytoreduction because of less
chemosensitive disease and milder chemotherapy. This might
Figure 5. Peak TRF length according to GC experi-
ence. (A) Peak TRF length in GC-experienced and
GC-inexperienced tumors, classified according to the
presence or absence of somatic hypermutation. (B) GC-
experienced tumors are divided into GC derived and
post-GC–derived according to the presence or absence
of ongoing somatic hypermutation. (C) How TRF length
correlates with GC experience in CLL patients. Box plots
indicate 25th percentile, median value, and 75th percen-
tile (horizontal lines of rectangle from the bottom, respec-
tively) and 10th and 90th percentiles (horizontal lines
outside rectangle).
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explain why they displayed TRF lengths similar to those observed
at diagnosis in patients with analogous tumors.
In addition to their biologic relevance to MBCLD pathogenesis,
our findings are of clinical interest because telomerase is now
regarded as one of the most promising targets for anticancer
treatment. Antisense oligonucleotides and small molecules such as
BIBR-153224-26,47 have been evaluated in vitro as anticancer agents
for solid tumors, and they may soon become significant in the
treatment of hematologic cancers. Telomerase inhibitors act through
several mechanisms, including induction of pharmacologic senes-
cence and triggering of apoptosis.26,47,48 Although the mechanism
of telomerase inhibitors is probably not only telomere oriented,
theoretical considerations and in vitro experiments indicate that
their therapeutic effects will be particularly pronounced in the
presence of short telomeres. Our results indicate that these agents
may be particularly suitable for the treatment of MCL and
VH-unmutated CLL. In contrast, the long telomeres of FCL and
DLCL cells might potentially protect cancer cells from pharmaco-
logically induced senescence for a long time. At our laboratory we
are performing in vitro cell line studies to verify this hypothesis.
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